SEC 13F Intelligence

Clal Insurance Enterprises Holdings Ltd / KROS

Clal Insurance Enterprises Holdings Ltd’s Keros Therapeutics Inc Position

Does Clal Insurance Enterprises Holdings Ltd own Keros Therapeutics Inc (KROS)? Not currently — the last reported position was 299.0K shares worth $12M in Q2 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$12M
Q2 2023
Shares
299.0K
% of Portfolio
+0.14%
Quarters Held
11
position exited

Position History KROS

Reported value by quarter
Q4 ’20: $21MQ4 ’20Q1 ’21: $20MQ2 ’21: $14MQ2 ’21Q3 ’21: $12MQ4 ’21: $19MQ4 ’21Q1 ’22: $17MQ2 ’22: $8MQ2 ’22Q3 ’22: $11MQ4 ’22: $14MQ4 ’22Q1 ’23: $13MQ2 ’23: $12MQ2 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2023299.0K$12M+0.14%
Q1 2023299.0K$13M+0.19%
Q4 2022299.0K$14M+0.22%
Q3 2022299.0K$11M+0.15%
Q2 2022299.0K$8M+0.11%
Q1 2022320.0K$17M+0.18%
Q4 2021320.0K$19M+0.20%
Q3 2021311.1K$12M+0.14%
Q2 2021320.0K$14M+0.16%
Q1 2021320.0K$20M+0.23%
Q4 2020320.0K$21M+0.29%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Clal Insurance Enterprises Holdings Ltd’s full portfolio or all institutional holders of KROS.